MedTrace Logo

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

NCT06879691 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2025-03-17

No results posted yet for this study

Summary

The purpose of this study is to investigate the impact of combining Nimotuzumab with analgesic agents on pain management outcomes, as well as the effectiveness and safety profile of this therapeutic combination in the comprehensive treatment of locally advanced head and neck squamous cell carcinoma.

Conditions

Interventions

DRUG

Nimotuzumab

nimotuzumab group nimotuzumab, 200mg/w, for 6 weeks

DRUG

cis-platinum

30mg/m2/w, for 6 weeks

RADIATION

IMRT combine with cisplatin concurrent chemotherapy

IMRT, 66～70Gy (2Gy/F, 35F), for 6 weeks

DRUG

painkiller

three ladders pain analgesic( First step: For mild pain, non-opioid agents (excluding nonsteroidal anti-inflammatory drugs \[NSAIDs\]) combined with adjuvant analgesics are administered; Second step: For moderate pain, weak opioids combined with NSAIDs and adjuvant analgesics are prescribed;Third step: For severe pain, strong opioids combined with NSAIDs and adjuvant analgesics are used.)

Sponsors & Collaborators

  • Baotou Cancer Hospital

    collaborator OTHER

  • Biotech Pharmaceutical Co., Ltd.

    lead OTHER

Principal Investigators

  • BO HAN · Baotou Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2025-04-14
Completion
2025-04-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879691 on ClinicalTrials.gov